Fig 1: Comparison of urine biomarkers among patients with SLE, LN, and healthy controls. (A) Urine level of ALCAM. (B) Urine level of HPX. (C) Urine level of PRDX6. Statistical analyses were conducted using the Mann–Whitney U test. SLE, systemic lupus erythematosus; LN, lupus nephritis; ALCAM, activated leukocyte cell adhesion molecule; HPX, hemopexin; PRDX, peroxiredoxin.
Fig 2: Changes in urine biomarker levels in follow-up observations of patients with SLE without LN and patients with LN. (A) Urine level of ALCAM. (B) Urine level of HPX. (C) Urine level of PRDX6. Statistical analyses were conducted using the Mann–Whitney U test. SLE, systemic lupus erythematosus; LN, lupus nephritis; ALCAM, activated leukocyte cell adhesion molecule; HPX, hemopexin; PRDX, peroxiredoxin.
Fig 3: Association between changes in biomarker levels and disease activity during follow-up examinations. (A) Correlation between ΔALCAM and ΔSLEDAI-2k. (B) Correlation between HPX and SLEDAI-2k. (C) Correlation between Δ PRDX6 and ΔSLEDAI-2k. SLEDAI, SLE disease activity index 2000; ALCAM, activated leukocyte cell adhesion molecule; HPX, hemopexin; PRDX, peroxiredoxin.
Fig 4: Changes in urine biomarker Levels of patients with SLE without LN and patients with LN only follow-up. (A) Urine level of ALCAM. (B) Urine level of HPX. (C) Urine level of PRDX6. Statistical analyses were conducted using the Mann–Whitney U test. SLE, systemic lupus erythematosus; LN, lupus nephritis; ALCAM, activated leukocyte cell adhesion molecule; HPX, hemopexin; PRDX, peroxiredoxin.
Supplier Page from MyBioSource.com for Human Peroxiredoxin 6 ELISA Kit